智通财经APP讯,维亚生物(01873)公布2024年业绩,收入约19.867亿元,同比减少7.8%。毛利约6.87亿元,同比减少6.9%。净利润2.22亿元,同比扭亏为盈。基本每股盈利0.08元。
公告称,收入减少主要由于全球生物医药投资减少对创新药物研发的影响;主要品种涉及的现有原料药车间进行升级,以更好地满足客户的FDA审核需求;及CDMO分部内客户订单延期。
扭亏为盈主要得益于因可转债的全额偿还而带来相关财务调整项的消除。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.